UD professor earns $400K+ for new brain study
University of Dayton biology professor Pothitos M. Pitychoutis, is receiving a grant of $413,681 to study a potential catalyst for conditions such as autism, schizophrenia and ADHD.
The purpose behind the study is to find more effective and safer treatments for these conditions.
'Overall, gaining insights into the regulation of calcium-cycling processes in the brain may pave the way for developing new, safer and more effective drug therapies for the treatment of these debilitating and costly brain disorders,' Pitychoutis said.
Pitychoutis' study will see a closer look at phospholamban, the calcium-handling protein and its impact in the part of the brain that manages sleep, attention and how we process stimuli around us.
The grant will help with Pitychoutis' efforts as well as opportunities available for UD students.
'Working on this project will help prepare some of our talented students to pursue postgraduate studies in neuroscience and follow careers in industry and academia, as well as in biomedical and health-related professions,' Pitychoutis said.
While the university currently hosts a neuroscience minor, the program will expand to serve as a major for students beginning this fall.
For more information on the study and the grant award to Pitychoutis, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
ADHD drugs have wider life benefits, study suggests
Drug treatment can help people newly diagnosed with ADHD (attention deficit hyperactivity disorder) to reduce their risk of substance misuse, suicidal behaviour, transport accidents and criminality, a study suggests. These issues are linked to common ADHD symptoms such as acting impulsively and becoming easily distracted. Some 5% of children and 2.5% of adults worldwide are thought to be affected by the disorder - and growing numbers are being diagnosed. The findings, published in the British Medical Journal (BMJ), confirm the wider potential benefits of drug treatment and could help patients decide whether to start medication, the researchers say. Having ADHD means the brain works differently to most other people's. Symptoms can include difficulties concentrating and sitting still, having high energy levels and being impulsive. Despite the surge in people asking for help, the disorder is not becoming more common. Last year a BBC investigation found long waits for assessment in the UK. People are only diagnosed if the symptoms cause at least a moderate impact on their lives. The most commonly prescribed drugs, called stimulants, help manage everyday symptoms but there has been limited evidence of longer-term benefits for people's behaviour, while well-publicised side-effects, such as headaches, loss of appetite and trouble sleeping, have sparked debate on their safety. How many of us will end up being diagnosed with ADHD? Greater awareness behind ADHD surge, study suggests This BMJ study was based on 148,500 people aged six to 64, with ADHD in Sweden. Some 57% started drug treatment and, of these, methylphenidate (also known as Ritalin), was prescribed, to 88%. The researchers, from Southampton University and the Karolinska Institute in Stockholm, found taking ADHD medication was linked to reductions of first-time instances of: suicidal behaviour - 17% substance misuse - 15% transport accidents - 12% criminal behaviour - 13% When recurrent events were analysed, the researchers found ADHD medication was linked to reductions of: 15% for suicide attempts 25% for substance misuses 4% for accidental injuries 16% for transport accidents 25% for criminal behaviour "Oftentimes there is no information on what the risks are if you don't treat ADHD," said Prof Samuele Cortese, study author and professor of child and adolescent psychiatry at University of Southampton. "Now we have evidence they [drugs] can reduce these risks." This could be explained by medication reducing impulsive behaviour and lack of concentration, which might reduce the risk of accidents while driving and reduce aggressive behaviour which could lead to criminality. The researchers say the study was designed to be as robust as possible but cannot rule out the possibility the results were affected by factors such as people's genes, lifestyles and the severity of their ADHD. Accessing the right medication for ADHD in many countries is not easy, with some drugs in short supply. In the UK waiting times to see specialists after diagnosis in order to access drugs can be several years. Prof Stuart Kinner, head of the Justice Health Group at Curtin University in Western Australia, said the research demonstrated "the diffuse benefits of ADHD diagnosis and treatment". "Failure to diagnose and treat ADHD can lead to self-medication with alcohol or other drugs, poor mental health, injury, and incarceration," he said. "Too many people with undiagnosed ADHD end up in the criminal justice system, where their condition may remain undiagnosed and untreated." Ian Maidment, professor in clinical pharmacy at Aston University, said the study "adds to our understanding of the potential benefits of these drugs". However, he said the research did not assess whether patients actually took their medication or the impact of different doses. Eight-year ADHD backlog at NHS clinics revealed Adult ADHD diagnosis 'tough but totally made sense' NHS cannot meet autism or ADHD demand, report says Seven-fold increase in adult ADHD prescriptions WATCH BBC iPlayer - Inside Our ADHD Minds
Bloomberg
9 hours ago
- Bloomberg
ADHD Medicines Reduce Suicide, Crime Risks in Sweeping Study
Drugs to treat attention deficit hyperactivity disorder were linked to a reduced risk of suicidal behavior, substance misuse and criminality in the first research of its kind. The findings come amid increasing debate around whether ADHD is being over-diagnosed and therefore over-treated with drugs like Ritalin. The research published in the British Medical Journal on Wednesday did not investigate whether patients are being accurately diagnosed, but it does provide evidence supporting medical treatment.
Time Business News
12 hours ago
- Time Business News
Zoloft vs Lexapro: Cardiovascular Health Considerations
When choosing an antidepressant, it is essential to consider not only the effectiveness for mood disorders but also potential impacts on cardiovascular health. Two commonly prescribed selective serotonin reuptake inhibitors (SSRIs), zoloft vs lexapro, are often compared for their efficacy, side effects, and safety profile, including how they may affect the heart and blood vessels. Understanding the cardiovascular considerations of these medications can help patients and healthcare providers make informed decisions. Finding the right treatment for adults who struggle with both ADHD and anxiety can be challenging. Certain medications designed for ADHD may sometimes worsen anxiety, while others can help manage both conditions simultaneously. Stimulant options like methylphenidate and non-stimulants such as atomoxetine are commonly evaluated by doctors based on individual needs. In the middle of this process, many patients discover that the best ADHD medication for adults with anxiety balances focus improvement without amplifying anxious feelings. Consulting a healthcare professional is essential, as personalized treatment ensures both attention and emotional well-being are addressed safely and effectively. Zoloft and Lexapro are both SSRIs, a class of medications that increase serotonin levels in the brain to improve mood and alleviate symptoms of depression and anxiety. Zoloft is approved for major depressive disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder. Lexapro is primarily prescribed for major depressive disorder and generalized anxiety disorder. While both medications are effective for mood regulation, their pharmacological differences can influence cardiovascular health in varying ways. SSRIs, in general, are considered to have a relatively safe cardiovascular profile compared to older classes of antidepressants such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). However, SSRIs can still impact heart health, particularly in patients with preexisting cardiovascular conditions. Common concerns include changes in heart rate, blood pressure, and electrical conduction in the heart, which may lead to arrhythmias or prolonged QT intervals in susceptible individuals. Additionally, SSRIs can influence platelet function, potentially affecting bleeding risk and cardiovascular events in some patients. Zoloft has been studied extensively for its cardiovascular safety. Research suggests that Zoloft is generally well-tolerated in patients with heart disease. It is often considered a first-line SSRI for individuals with cardiovascular risk factors because it has a lower likelihood of causing significant changes in blood pressure or heart rhythm. However, some studies indicate that high doses of Zoloft may cause mild increases in heart rate or occasional palpitations. Patients with a history of arrhythmias or other heart conditions should be monitored closely when taking Zoloft. Lexapro is also considered to have a favorable cardiovascular profile, but it differs slightly from Zoloft in its impact on heart function. Lexapro has been associated with mild changes in QT interval on electrocardiograms, particularly at higher doses or in combination with other medications that prolong the QT interval. This could theoretically increase the risk of arrhythmias, though the absolute risk remains low for most patients. Like Zoloft, Lexapro can influence platelet function and may slightly increase bleeding risk, especially when combined with anticoagulants or antiplatelet drugs. Patients with a history of prolonged QT interval or heart rhythm abnormalities should use Lexapro under close medical supervision. When comparing Zoloft and Lexapro in terms of cardiovascular health, both medications are generally considered safe for the majority of patients, but subtle differences exist. Zoloft may be preferred for patients with preexisting arrhythmias or those at risk of heart rhythm disturbances, as it is less likely to prolong the QT interval. Lexapro, while effective and well-tolerated for depression and anxiety, requires caution in individuals with known QT prolongation or those taking other medications that affect cardiac conduction. Both medications require monitoring in patients with significant cardiovascular conditions, and healthcare providers typically perform baseline electrocardiograms and regular follow-ups as needed. In addition to medication choice, patients should focus on lifestyle factors that support heart health while taking SSRIs. Regular exercise, a balanced diet, maintaining a healthy weight, and avoiding smoking can reduce cardiovascular risk. Monitoring blood pressure and heart rate, particularly in the early stages of treatment, can help detect any potential issues before they become serious. Patients should also report any symptoms such as palpitations, dizziness, fainting, or unusual fatigue to their healthcare provider promptly. Zoloft and Lexapro are effective SSRIs with generally favorable cardiovascular safety profiles, but individual factors play a crucial role in determining the most appropriate medication. Zoloft may offer a slight advantage for patients with heart rhythm concerns, whereas Lexapro requires careful monitoring in individuals with QT prolongation risk. Both medications should be used under the guidance of a healthcare provider, with regular monitoring and attention to lifestyle habits that promote cardiovascular health. By understanding the subtle differences in how these medications affect the heart, patients and clinicians can make informed decisions that support both mental and cardiovascular well-being. TIME BUSINESS NEWS
